3718-02-3

Upstream product

• 2622-63-1 1-methyl-2-phenylbenzimidazole 
• 99-61-6 3-nitro-benzaldehyde 
• 4760-34-3 N-methyl-1,2-phenylenediamine 
• 15456-62-9 2-(3-nitrophenyl)-1H-benzimidazole 
• 74-88-4 methyl iodide 
• 121-90-4 m-nitrobenzoic acid chloride 
• 95-54-5 1,2-diamino-benzene 
• 65953-23-3 3-nitro-N-[2-[(3-nitrobenzoyl)amino]phenyl]benzamide 

Downstream Products

• 717102-89-1 3-(1-methyl-1H-benzimidazol-2-yl)-phenylamine 
• 717102-90-4 2-chloro-N-[3-(1-methyl-1H-benzimidazol-2-yl)-phenyl]acetamide 

Relevant academic research and scientific papers

Metal complex, synthetic method and application thereof in organic electroluminescence device

The invention discloses a metal complex, a synthetic method and application thereof in an organic electroluminescence device. The general formula of the metal complex is (the formula is shown in the description), wherein R1 is selected from a substituted

Meta-Selective CAr-H Nitration of Arenes through a Ru3(CO)12-Catalyzed Ortho-Metalation Strategy

The first example of transition metal-catalyzed meta-selective CAr-H nitration of arenes is described. With the use of Ru3(CO)12 as the catalyst and Cu(NO3)2·3H2O as the nitro source, a wide spectrum of arenes bearing diversified N-heterocycles or oximido as the directing groups were nitrated with meta-selectivity exclusively. Mechanism studies have demonstrated the formation of a new 18e-octahedral ruthenium species as a key ortho-CAr-H metalated intermediate, which may be responsible for the subsequent meta-selective electrophilic aromatic substitution (SEAr). Moreover, this approach provides a fast-track strategy for atom/step economical synthesis of many useful pharmaceutical molecules.

Design and synthesis of 2-arylbenzimidazoles and evaluation of their inhibitory effect against Chlamydia pneumoniae

Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer's disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 μM, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 μM against CWL-029 and 6.3 μM against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.

A Keggin heteropoly acid as an efficient catalyst for an expeditious, one-pot synthesis of 1-methyl-2-(hetero)arylbenzimidazoles

The Keggin heteropoly acid, silicotungstic acid, H4SiW12O40, has been demonstrated to be highly efficient for an expeditious, one-pot synthesis of 1-methyl-2-(hetero)arylbenzimidazoles from N-methyl-1,2-phenylenediamine and (hetero)aryl aldehydes in ethyl acetate at room temperature. The catalyst works equally well for N-phenyl-1,2-phenylenediamine.

Synthesis and antimicrobial activities of some new benzimidazole derivatives

Some benzimidazolylbenzamides were synthesized and their antimicrobial activities against Staphylococcus aureus, Streptococcus faecalis, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa and Candida albicans evaluated. It was shown that the compound 14 exhibited the best activity against B. subtilis, P. aeruginosa and C. albicans.